Please provide your email address to receive an email when new articles are posted on . In this video, Alokkumar Jha, PhD, MSc, BE, spoke with Healio about key presentations from the American ...
WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL) (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the ...
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel ...
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
Dr. Avindra Nath, Clinical Director of National Institute of Neurological Disorders and Stroke (NINDS), presented novel pre-clinical results of the Amyotrophic lateral sclerosis (ALS) research program ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension ...
Scientists have conducted a systematic review and meta-analysis to evaluate the prevalence of neuropsychiatric manifestations associated with monkeypox infection. The review article has recently been ...
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results